Role of Rab GTPases in Hepatocellular Carcinoma
Chun-Cheng Yang,1,* Guang-Xiao Meng,1,* Zhao-Ru Dong,1,* Tao Li1,2 1Department of General Surgery, Qilu Hospital, Shandong University, Jinan, People’s Republic of China; 2Department of Hepatobiliary Surgery, The Second Hospital of Shandong University, Jinan, People’s Republic...
Enregistré dans:
Auteurs principaux: | Yang CC, Meng GX, Dong ZR, Li T |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/8934e8c52eb3484a95d672ce9a3b388b |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Lenvatinib as the key component of first-line therapy for patients with unresectable hepatocellular carcinoma
par: L. V. Bolotina
Publié: (2020) -
Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib
par: Pomej K, et autres
Publié: (2021) -
Nectin stabilization at adherens junctions is counteracted by Rab5a-dependent endocytosis
par: Pasquale Cervero, et autres
Publié: (2021) -
Focus on the Small GTPase Rab1: A Key Player in the Pathogenesis of Parkinson’s Disease
par: José Ángel Martínez-Menárguez, et autres
Publié: (2021) -
Intraarterial contrast-enhanced ultrasound to predict the short-term tumour response of hepatocellular carcinoma to Transarterial chemoembolization with Lipiodol
par: Jiang Bo, et autres
Publié: (2021)